Takeda Pharmaceutical Company Limited (TAK)
After hours:
| Previous Close | 15.89 |
| Open | 15.76 |
| Bid | 0.00 x 28000 |
| Ask | 15.79 x 4000 |
| Day's Range | 15.69 - 15.83 |
| 52 Week Range | 12.28 - 16.30 |
| Volume | |
| Avg. Volume | 2,807,720 |
| Market Cap | 49.22B |
| Beta (5Y Monthly) | 0.75 |
| PE Ratio (TTM) | 30.04 |
| EPS (TTM) | 0.53 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.73 (5.60%) |
| Ex-Dividend Date | Mar 30, 2022 |
| 1y Target Est | 17.63 |
- GlobeNewswire
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
— HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S., Europe and Japan planned to complete in 2023 — — Partnership approach aligned with HUTCHMED’s path to profitability and strategy to bring its innovative medicines to patients worldwide — — HUTCHMED to host a conference call and webcast at 8:30 a.m. EST (1:30 p.
- Business Wire
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
OSAKA, Japan & CAMBRIDGE, Mass., January 23, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with HUTCHMED (China) Limited (Nasdaq/AIM: HCM, HKEX: 13) and its subsidiary HUTCHMED Limited, for the further development and commercialization of fruquintinib outside of mainland China, Hong Kong and Macau.
- Reuters
Slumping China-bound Japanese exports raise fears of global downturn
Japan's export growth slowed sharply in December as China-bound shipments fell for the first time in seven months, stoking fears of further slowdown in the global economy and external demand for Japanese shipments. Exports rose 11.5% year-on-year in December after a gain of 20% in November, marking the slowest growth since the start of 2022, dragged down by a fall-off in sales to China of cars, auto parts and chip-making machinery, Ministry of Finance (MOF) data showed on Thursday. Exports to largest trading partner China fell 6.2% year-on-year in value and were down 24% in volume terms in December.
